The new Essilor Stellest 2.0 lenses deliver significantly higher efficacy in slowing the axial elongation of the eye that causes myopic vision. A recent study shows that the new design further supports effective myopia management by generating a stronger optical signal, delivering double the mean optical power. Drawing on the success of the Essilor Stellest lens—the first-ever FDA-market authorised spectacle lens clinically proven to slow down myopia progression in children—Essilor Stellest 2.0 lenses are currently available in Greater China, with expansion to other key markets planned from 2026.
Recognising the critical role of delaying myopia onset in long-term management, Essilor Stellest plano pair lenses is moving toward early intervention by introducing clinically validated solutions for children at risk of developing myopia. Clinical research shows that postponing myopia onset by just one year can offer benefits comparable to over two years of slowed progression. One of the world’s first randomised, controlled, independent trials on plano lenses for delaying myopia onset found that children aged 6–12 at risk of myopia who wore Essilor Stellest plano pair lenses for more than 30 hours per week experienced slower axial elongation. This innovation marks a major step from myopia management toward evidence-based prevention. Essilor Stellest plano pair lenses are available in Greater China.
Essilor Stellest Smartglasses
At CIIE, EssilorLuxottica also showcased the Essilor Stellest Smartglasses for the first time, expanding its smart technologies to the Essilor Stellest brand. Equipped with Essilor Stellest lenses, the glasses track wearing time and patterns, provide behavioural insights and help respect wearing compliance, critical to the efficiency in myopia management. Essilor Stellest Smartglasses will be available in Mainland China starting in 2026.
“At the forefront of med-tech innovation, we are transforming myopia management with our Essilor Stellest platform. By combining advanced lens technology with smart features, we enable early intervention, promote healthy wearing habits and accelerate progress in slowing myopia progression in children. Our purpose is clear: turning evidence into action and technology into empowerment. By working closely with industry partners and advancing evidence-based innovation, we aim to deliver even more groundbreaking solutions, reinforcing our commitment to advancing eye health for the next generation,” said Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO of EssilorLuxottica.
